Table 2 Summary of responses of MET activating mutations to combined targeted therapy
Study | Type | Driver mutation | MET alterations | Treatment | Best response |
|---|---|---|---|---|---|
Kuang et al. [21] | In vivo | EGFR 19-Del | MET-D1228N | Osimertinib + cabozantinib | PR |
Kang et al. [22] | In vivo | EGFR-L858R | MET-D1228N/H, MET-Y1230H, MET-D1231Y | Osimertinib + cabozantinib | PD |
Schoenfeld et al. [23] | In vitro | EGFR-S768I + V769L | MET-H1094R/Y | Osimertinib + crizotinib | NA |